Literature DB >> 8410057

Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides.

J C García Moncó1, C M Wheeler, J L Benach, R A Furie, S A Lukehart, G Stanek, A C Steere.   

Abstract

A subset of patients (50%) with neuroborreliosis (Lyme disease) showed IgG reactivity to cardiolipin in solid phase ELISA. In addition, a subset of patients with neuroborreliosis (29%) and syphilis (59%) had IgM reactivity to gangliosides with a Gal(beta 1-3) GalNac terminal sequence (GM1, GD1b, and asialo GM1). Anti-ganglioside IgM antibodies were significantly more frequent in these two groups of patients compared to patients with cutaneous and articular Lyme disease, primary antiphospholipid syndrome, systemic lupus erythematosus and normal controls. Correlative evidence and adsorption experiments indicated that antibodies to cardiolipin had separate specificities from those directed against the gangliosides. IgM antibodies to Gal(beta 1-3) GalNac gangliosides appeared to have similar specificities since these were positively correlated and inhibitable by cross adsorption assays. Given the clinical associations of patients with neuroborreliosis and syphilis with IgM reactivity to gangliosides sharing the Gal(beta 1-3) GalNac terminus, we suggest that these antibodies could represent a response to injury in neurological disease or a cross reactive event caused by spirochetes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410057     DOI: 10.1016/0022-510x(93)90175-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  18 in total

1.  Borrelia burgdorferi HtrA: evidence for twofold proteolysis of outer membrane protein p66.

Authors:  James L Coleman; Alvaro Toledo; Jorge L Benach
Journal:  Mol Microbiol       Date:  2015-10-20       Impact factor: 3.501

Review 2.  Host-pathogen interactions in the immunopathogenesis of Lyme disease.

Authors:  L T Hu; M S Klempner
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

3.  Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.

Authors:  Diane G Edmondson; Sabitha Prabhakaran; Steven J Norris; Amy J Ullmann; Joe Piesman; Marc Dolan; Christian Probst; Christiane Radzimski; Winfried Stöcker; Lars Komorowski
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

4.  Targeting CXCL13 During Neuroinflammation.

Authors:  Amanda K Huber; David N Irani
Journal:  Adv Neuroimmune Biol       Date:  2015-11-13

5.  Cholesterol lipids of Borrelia burgdorferi form lipid rafts and are required for the bactericidal activity of a complement-independent antibody.

Authors:  Timothy J LaRocca; Jameson T Crowley; Brian J Cusack; Priyadarshini Pathak; Jordi Benach; Erwin London; Juan C Garcia-Monco; Jorge L Benach
Journal:  Cell Host Microbe       Date:  2010-10-21       Impact factor: 21.023

6.  Lipid rafts can form in the inner and outer membranes of Borrelia burgdorferi and have different properties and associated proteins.

Authors:  Alvaro Toledo; Zhen Huang; James L Coleman; Erwin London; Jorge L Benach
Journal:  Mol Microbiol       Date:  2018-02-15       Impact factor: 3.501

7.  Experimental immunization with Borrelia burgdorferi induces development of antibodies to gangliosides.

Authors:  J C Garcia-Monco; R J Seidman; J L Benach
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

8.  Borrelia burgdorferi shows specificity of binding to glycosphingolipids.

Authors:  P B Backenson; J L Coleman; J L Benach
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

9.  Lipid exchange between Borrelia burgdorferi and host cells.

Authors:  Jameson T Crowley; Alvaro M Toledo; Timothy J LaRocca; James L Coleman; Erwin London; Jorge L Benach
Journal:  PLoS Pathog       Date:  2013-01-10       Impact factor: 6.823

10.  Proving lipid rafts exist: membrane domains in the prokaryote Borrelia burgdorferi have the same properties as eukaryotic lipid rafts.

Authors:  Timothy J LaRocca; Priyadarshini Pathak; Salvatore Chiantia; Alvaro Toledo; John R Silvius; Jorge L Benach; Erwin London
Journal:  PLoS Pathog       Date:  2013-05-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.